Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.
Webcast details and replay access are available via the company Events page; webcasts remain available for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – CRBU
In the May 6 session, CRBU gained 1.04%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Regulatory designation | Positive | +10.5% | FDA RMAT designation for CB-011 based on promising CaMMouflage trial data. |
| Mar 05 | Earnings and update | Positive | +6.4% | Full-year 2025 results with cash position and CAR-T pipeline progress details. |
| Feb 12 | Investor conferences | Neutral | +4.0% | Announcement of management participation in upcoming investor conferences. |
| Feb 04 | Clinical data update | Positive | +3.9% | Late-breaking presentations with updated clinical and translational CAR-T data. |
| Dec 01 | KOL event | Neutral | -0.6% | Planned in-person and virtual KOL event at ASH 2025 on vispa-cel. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Substantive regulatory and clinical updates (RMAT designation, earnings with pipeline progress) have generally seen positive price alignment, while neutral event announcements show mixed, often divergent reactions.
Over the last six months, Caribou Biosciences has reported several notable developments. On Mar 31, 2026, FDA granted RMAT designation to CB-011 based on strong early efficacy, and the stock rose 10.47%. The Mar 5, 2026 earnings update highlighted 2025 revenue, reduced R&D and G&A expenses, and cash of $142.8M, with a 6.43% gain. Multiple conference and event announcements, including February investor conferences and scientific presentations, produced smaller, sometimes divergent moves, showing that markets react more strongly to clinical and regulatory catalysts than to routine appearances.
Key Terms
crispr medical
genome-editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at BofA Securities 2026 Health Care Conference on May 13, 2026, at 8:40am PT in Las Vegas, Nevada.
For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
